APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gout Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Gout Drugs Market Outlook and Growth Opportunities 2026

20 December 2025190 pages

Choose your research edition.

Industry ResearchGout Drugs Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Gout Drugs Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Gout Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gout Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Gout Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Gout Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Gout Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gout Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gout Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Gout Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Gout Drugs market include Accord, Apotex, Ipca, KPC, Northstar, PIDI, Synpac-Kingdom, Mylan and Sun Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Gout Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gout Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gout Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Gout Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Gout Drugs Segment by Company

Accord

Apotex

Ipca

KPC

Northstar

PIDI

Synpac-Kingdom

Mylan

Sun Pharma

Yunnan Phytopharmaceutical

Gout Drugs Segment by Type

Benzbromo Malone

Allopurinol

Febuxostat

Colchicine

Other

Gout Drugs Segment by Application

Acute gout

Chronic gout

Gout Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Gout Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Gout Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gout Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Gout Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gout Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gout Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gout Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Gout Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gout Drugs industry.

Chapter 3: Detailed analysis of Gout Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Gout Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Gout Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gout Drugs Industry Trends Table 2. Gout Drugs Industry Drivers Table 3. Gout Drugs Industry Opportunities and Challenges Table 4. Gout Drugs Industry Restraints Table 5. Global Gout Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gout Drugs Revenue Share by Company (2021-2026) Table 7. Global Gout Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Gout Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Gout Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Gout Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Gout Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Gout Drugs Company, Product Type & Application Table 13. Global Gout Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Gout Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Benzbromo Malone Table 18. Significant Companies of Allopurinol Table 19. Significant Companies of Febuxostat Table 20. Significant Companies of Colchicine Table 21. Significant Companies of Other Table 22. Global Gout Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Gout Drugs Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Gout Drugs Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Gout Drugs Sales Volume Share by Type (2021-2026) Table 26. Global Gout Drugs Sales Volume Share by Type (2027-2032) Table 27. Global Gout Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Gout Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Gout Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Gout Drugs Sales Value Share by Type (2021-2026) Table 31. Global Gout Drugs Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Acute gout Table 33. Significant Companies of Chronic gout Table 34. Global Gout Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Gout Drugs Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Gout Drugs Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Gout Drugs Sales Volume Share by Application (2021-2026) Table 38. Global Gout Drugs Sales Volume Share by Application (2027-2032) Table 39. Global Gout Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Gout Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Gout Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Gout Drugs Sales Value Share by Application (2021-2026) Table 43. Global Gout Drugs Sales Value Share by Application (2027-2032) Table 44. Global Gout Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Gout Drugs Sales by Region (2021-2026) & (K Units) Table 46. Global Gout Drugs Sales Market Share by Region (2021-2026) Table 47. Global Gout Drugs Sales by Region (2027-2032) & (K Units) Table 48. Global Gout Drugs Sales Market Share by Region (2027-2032) Table 49. Global Gout Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Gout Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Gout Drugs Sales Value Share by Region (2021-2026) Table 52. Global Gout Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Gout Drugs Sales Value Share by Region (2027-2032) Table 54. Global Gout Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Gout Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Gout Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Gout Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Gout Drugs Sales by Country (2021-2026) & (K Units) Table 59. Global Gout Drugs Sales Market Share by Country (2021-2026) Table 60. Global Gout Drugs Sales by Country (2027-2032) & (K Units) Table 61. Global Gout Drugs Sales Market Share by Country (2027-2032) Table 62. Global Gout Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Gout Drugs Sales Value Market Share by Country (2021-2026) Table 64. Global Gout Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Gout Drugs Sales Value Market Share by Country (2027-2032) Table 66. Accord Company Information Table 67. Accord Business Overview Table 68. Accord Gout Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Accord Gout Drugs Product Portfolio Table 70. Accord Recent Development Table 71. Apotex Company Information Table 72. Apotex Business Overview Table 73. Apotex Gout Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Apotex Gout Drugs Product Portfolio Table 75. Apotex Recent Development Table 76. Ipca Company Information Table 77. Ipca Business Overview Table 78. Ipca Gout Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Ipca Gout Drugs Product Portfolio Table 80. Ipca Recent Development Table 81. KPC Company Information Table 82. KPC Business Overview Table 83. KPC Gout Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. KPC Gout Drugs Product Portfolio Table 85. KPC Recent Development Table 86. Northstar Company Information Table 87. Northstar Business Overview Table 88. Northstar Gout Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Northstar Gout Drugs Product Portfolio Table 90. Northstar Recent Development Table 91. PIDI Company Information Table 92. PIDI Business Overview Table 93. PIDI Gout Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. PIDI Gout Drugs Product Portfolio Table 95. PIDI Recent Development Table 96. Synpac-Kingdom Company Information Table 97. Synpac-Kingdom Business Overview Table 98. Synpac-Kingdom Gout Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Synpac-Kingdom Gout Drugs Product Portfolio Table 100. Synpac-Kingdom Recent Development Table 101. Mylan Company Information Table 102. Mylan Business Overview Table 103. Mylan Gout Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Mylan Gout Drugs Product Portfolio Table 105. Mylan Recent Development Table 106. Sun Pharma Company Information Table 107. Sun Pharma Business Overview Table 108. Sun Pharma Gout Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Sun Pharma Gout Drugs Product Portfolio Table 110. Sun Pharma Recent Development Table 111. Yunnan Phytopharmaceutical Company Information Table 112. Yunnan Phytopharmaceutical Business Overview Table 113. Yunnan Phytopharmaceutical Gout Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Yunnan Phytopharmaceutical Gout Drugs Product Portfolio Table 115. Yunnan Phytopharmaceutical Recent Development Table 116. Key Raw Materials Table 117. Raw Materials Key Suppliers Table 118. Gout Drugs Distributors List Table 119. Gout Drugs Customers List Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Gout Drugs Product Image Figure 2. Global Gout Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gout Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Gout Drugs Sales (2021-2032) & (K Units) Figure 5. Global Gout Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Gout Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Benzbromo Malone Image Figure 10. Allopurinol Image Figure 11. Febuxostat Image Figure 12. Colchicine Image Figure 13. Other Image Figure 14. Global Gout Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Gout Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Gout Drugs Sales Volume Share by Type (2021-2032) Figure 17. Global Gout Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Gout Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Gout Drugs Sales Value Share by Type (2021-2032) Figure 20. Acute gout Image Figure 21. Chronic gout Image Figure 22. Global Gout Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Gout Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Gout Drugs Sales Volume Share by Application (2021-2032) Figure 25. Global Gout Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Gout Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Gout Drugs Sales Value Share by Application (2021-2032) Figure 28. Global Gout Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Gout Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Gout Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Gout Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Gout Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. North America Gout Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Gout Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Gout Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Gout Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Gout Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Gout Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. South America Gout Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Gout Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Gout Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Gout Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Gout Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Gout Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Gout Drugs Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Gout Drugs Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Benzbromo Malone
  • Allopurinol
  • Febuxostat
  • Colchicine
  • Other
Applications
  • Acute gout
  • Chronic gout
Companies covered
  • Accord
  • Apotex
  • Ipca
  • KPC
  • Northstar
  • PIDI
  • Synpac-Kingdom
  • Mylan
  • Sun Pharma
  • Yunnan Phytopharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Gout Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Gout Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Gout Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Gout Drugs Market Dynamics
  1. 2.1 Gout Drugs Industry Trends
  2. 2.2 Gout Drugs Industry Drivers
  3. 2.3 Gout Drugs Industry Opportunities and Challenges
  4. 2.4 Gout Drugs Industry Restraints
3 Gout Drugs Market by Company
  1. 3.1 Global Gout Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Gout Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Gout Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Gout Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Gout Drugs Company Ranking (2024-2026)
  6. 3.6 Global Gout Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Gout Drugs Company Product Type and Application
  8. 3.8 Global Gout Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Gout Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Gout Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Gout Drugs Market by Type
  1. 4.1 Gout Drugs Type Introduction
  2. 4.1.1 Benzbromo Malone
  3. 4.1.2 Allopurinol
  4. 4.1.3 Febuxostat
  5. 4.1.4 Colchicine
  6. 4.1.5 Other
  7. 4.2 Global Gout Drugs Sales Volume by Type
  8. 4.2.1 Global Gout Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Gout Drugs Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Gout Drugs Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Gout Drugs Sales Value by Type
  12. 4.3.1 Global Gout Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Gout Drugs Sales Value by Type (2021-2032)
  14. 4.3.3 Global Gout Drugs Sales Value Share by Type (2021-2032)
5 Gout Drugs Market by Application
  1. 5.1 Gout Drugs Application Introduction
  2. 5.1.1 Acute gout
  3. 5.1.2 Chronic gout
  4. 5.2 Global Gout Drugs Sales Volume by Application
  5. 5.2.1 Global Gout Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Gout Drugs Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Gout Drugs Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Gout Drugs Sales Value by Application
  9. 5.3.1 Global Gout Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Gout Drugs Sales Value by Application (2021-2032)
  11. 5.3.3 Global Gout Drugs Sales Value Share by Application (2021-2032)
6 Gout Drugs Regional Sales and Value Analysis
  1. 6.1 Global Gout Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gout Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Gout Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Gout Drugs Sales by Region (2027-2032)
  5. 6.3 Global Gout Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Gout Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Gout Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Gout Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Gout Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Gout Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Gout Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Gout Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Gout Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Gout Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Gout Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Gout Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Gout Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Gout Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Gout Drugs Sales Value Share by Country, 2025 VS 2032
7 Gout Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Gout Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gout Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Gout Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Gout Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Gout Drugs Sales by Country (2027-2032)
  6. 7.4 Global Gout Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Gout Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Gout Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Gout Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Gout Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Gout Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Gout Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Gout Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Gout Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Gout Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Gout Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Gout Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Gout Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Gout Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Gout Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Gout Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Gout Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Gout Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Gout Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Gout Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Gout Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Gout Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Gout Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Gout Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Gout Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Gout Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Gout Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Gout Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Gout Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Gout Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Gout Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Gout Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Gout Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Gout Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Gout Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Gout Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Gout Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Gout Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Gout Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Gout Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Gout Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Gout Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Gout Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Gout Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Gout Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Gout Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Gout Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Gout Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Gout Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Gout Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Gout Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Gout Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Gout Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Gout Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Gout Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Gout Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Gout Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Gout Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Gout Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Gout Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Gout Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Gout Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Gout Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Gout Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Gout Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Gout Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Gout Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Gout Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Gout Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Gout Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Gout Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Gout Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Gout Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Gout Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Gout Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Gout Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Gout Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Gout Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Gout Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Gout Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Gout Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Gout Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Gout Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Gout Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Gout Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Gout Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Gout Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Accord
  2. 8.1.1 Accord Company Information
  3. 8.1.2 Accord Business Overview
  4. 8.1.3 Accord Gout Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Accord Gout Drugs Product Portfolio
  6. 8.1.5 Accord Recent Developments
  7. 8.2 Apotex
  8. 8.2.1 Apotex Company Information
  9. 8.2.2 Apotex Business Overview
  10. 8.2.3 Apotex Gout Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Apotex Gout Drugs Product Portfolio
  12. 8.2.5 Apotex Recent Developments
  13. 8.3 Ipca
  14. 8.3.1 Ipca Company Information
  15. 8.3.2 Ipca Business Overview
  16. 8.3.3 Ipca Gout Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Ipca Gout Drugs Product Portfolio
  18. 8.3.5 Ipca Recent Developments
  19. 8.4 KPC
  20. 8.4.1 KPC Company Information
  21. 8.4.2 KPC Business Overview
  22. 8.4.3 KPC Gout Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 KPC Gout Drugs Product Portfolio
  24. 8.4.5 KPC Recent Developments
  25. 8.5 Northstar
  26. 8.5.1 Northstar Company Information
  27. 8.5.2 Northstar Business Overview
  28. 8.5.3 Northstar Gout Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Northstar Gout Drugs Product Portfolio
  30. 8.5.5 Northstar Recent Developments
  31. 8.6 PIDI
  32. 8.6.1 PIDI Company Information
  33. 8.6.2 PIDI Business Overview
  34. 8.6.3 PIDI Gout Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 PIDI Gout Drugs Product Portfolio
  36. 8.6.5 PIDI Recent Developments
  37. 8.7 Synpac-Kingdom
  38. 8.7.1 Synpac-Kingdom Company Information
  39. 8.7.2 Synpac-Kingdom Business Overview
  40. 8.7.3 Synpac-Kingdom Gout Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Synpac-Kingdom Gout Drugs Product Portfolio
  42. 8.7.5 Synpac-Kingdom Recent Developments
  43. 8.8 Mylan
  44. 8.8.1 Mylan Company Information
  45. 8.8.2 Mylan Business Overview
  46. 8.8.3 Mylan Gout Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Mylan Gout Drugs Product Portfolio
  48. 8.8.5 Mylan Recent Developments
  49. 8.9 Sun Pharma
  50. 8.9.1 Sun Pharma Company Information
  51. 8.9.2 Sun Pharma Business Overview
  52. 8.9.3 Sun Pharma Gout Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Sun Pharma Gout Drugs Product Portfolio
  54. 8.9.5 Sun Pharma Recent Developments
  55. 8.10 Yunnan Phytopharmaceutical
  56. 8.10.1 Yunnan Phytopharmaceutical Company Information
  57. 8.10.2 Yunnan Phytopharmaceutical Business Overview
  58. 8.10.3 Yunnan Phytopharmaceutical Gout Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Yunnan Phytopharmaceutical Gout Drugs Product Portfolio
  60. 8.10.5 Yunnan Phytopharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Gout Drugs Value Chain Analysis
  2. 9.1.1 Gout Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Gout Drugs Sales Mode & Process
  6. 9.2 Gout Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Gout Drugs Distributors
  9. 9.2.3 Gout Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst